Literature DB >> 19006190

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.

Roger Lane1, Yunsheng He, Christopher Morris, James B Leverenz, Murat Emre, Clive Ballard.   

Abstract

Apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample, associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE epsilon4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other genotypes. Subjects with hyperhomocysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE epsilon4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19006190     DOI: 10.1002/mds.22357

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  APOE DNA methylation is altered in Lewy body dementia.

Authors:  Jessica Tulloch; Lesley Leong; Sunny Chen; C Dirk Keene; Steven P Millard; Andrew Shutes-David; Oscar L Lopez; Julia Kofler; Jeffrey A Kaye; Randy Woltjer; Peter T Nelson; Janna H Neltner; Gregory A Jicha; Douglas Galasko; Eliezer Masliah; James B Leverenz; Chang-En Yu; Debby Tsuang
Journal:  Alzheimers Dement       Date:  2018-03-12       Impact factor: 21.566

2.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

3.  APOE ε4 increases risk for dementia in pure synucleinopathies.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

4.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

5.  Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Authors:  Valérie Leduc; Dorothée Domenger; Louis De Beaumont; Daphnée Lalonde; Stéphanie Bélanger-Jasmin; Judes Poirier
Journal:  Int J Alzheimers Dis       Date:  2011-04-05

6.  Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.

Authors:  Seiju Kobayashi; Masaru Tateno; Tae Woo Park; Kumiko Utsumi; Hitoshi Sohma; Yoichi M Ito; Yasuo Kokai; Toshikazu Saito
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

7.  Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort.

Authors:  Guro Berge; Sigrid B Sando; Arvid Rongve; Dag Aarsland; Linda R White
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-03-17       Impact factor: 10.154

Review 8.  Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy.

Authors:  Aintzane Urbizu; Katrin Beyer
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

9.  The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers.

Authors:  Manuel Fernández Martínez; Xabier Elcoroaristizabal Martín; Luís Galdos Alcelay; Jessica Castro Flores; Juan María Uterga Valiente; Begoña Indakoetxea Juanbeltz; María Angeles Gómez Beldarraín; Josefa Moraza López; María Carmen Gonzalez-Fernández; Ana Molano Salazar; Rocio Bereincua Gandarias; Sandra Inglés Borda; Nuria Ortiz Marqués; Miryam Barandiarán Amillano; María Carrasco Zabaleta; Marian M de Pancorbo
Journal:  BMC Neurosci       Date:  2009-09-30       Impact factor: 3.288

10.  Exome sequencing in dementia with Lewy bodies.

Authors:  M J Keogh; M Kurzawa-Akanbi; H Griffin; K Douroudis; K L Ayers; R I Hussein; G Hudson; A Pyle; H J Cordell; J Attems; I G McKeith; J T O'Brien; D J Burn; C M Morris; A J Thomas; P F Chinnery
Journal:  Transl Psychiatry       Date:  2016-02-02       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.